Indian Pharma Lobby Flays India-EU Trade Talks; Debunks "TRIPS Plus" Provisions On Patent Extensions And Data Protection
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hardball negotiations between Indian and European Union representatives on the signing of a free trade agreement may lead to flare ups after the Indian Pharmaceutical Alliance - a powerful industry lobby - raised strong objections on provisions related to intellectual property rights that are sought to be incorporated in the draft treaty
You may also be interested in...
Indian Lobby Warns Of Proposed EU-India Free Trade Agreement's Impact; Says Drug Supplies Of Developing Nations May Be In Jeopardy
MUMBAI - As India and the European Union draw closer to signing a comprehensive Free Trade Agreement, the Indian Pharmaceutical Alliance - an influential lobby group of leading Indian pharmaceutical companies - has appealed to the Indian government to exercise caution and abstain from giving in to EU's demands, particularly those that allegedly ask for "TRIPS plus" provisions to be incorporated in the Indian legal framework
Indian Lobby Warns Of Proposed EU-India Free Trade Agreement's Impact; Says Drug Supplies Of Developing Nations May Be In Jeopardy
MUMBAI - As India and the European Union draw closer to signing a comprehensive Free Trade Agreement, the Indian Pharmaceutical Alliance - an influential lobby group of leading Indian pharmaceutical companies - has appealed to the Indian government to exercise caution and abstain from giving in to EU's demands, particularly those that allegedly ask for "TRIPS plus" provisions to be incorporated in the Indian legal framework
Free Trade Agreements May Impede Supply Of AIDS Drugs From India, Says Study
MUMBAI - Regional and bilateral free trade agreements may seriously threaten future supplies of life-saving antiretroviral drugs from Indian companies, warned Geneva-based UNITAID - the agency that facilitates access to low-cost medicines in developing countries